Statistical Considerations for Clinical Trials During COVID-19: Independent DMC for Blinded Data Monitoring and Analysis

Authors

Qing LiuFollow
Karl E. Peace, Georgia Southern UniversityFollow

Document Type

Article

Publication Date

4-21-2020

Publication Title

LinkedIn

Abstract

To supplement both the FDA and EMA guidance, we describe the principles and key elements for developing a DMC chart for individual clinical trials affected by COVID-19.

Recommended Citation

Liu, Qing, Karl E. Peace. 2020. "Statistical Considerations for Clinical Trials During COVID-19: Independent DMC for Blinded Data Monitoring and Analysis." LinkedIn. source: Linkedin.com
https://digitalcommons.georgiasouthern.edu/bee-facpubs/148